France-based allergenics company Stallergenes (Euronext Paris: GENP) is to exercise the option to pursue the exclusive development of a new class of oral allergy treatments in partnership with Belgian biopharma company ActoGeniX.
The collaboration will focus on the development of a treatment approach based on allergen-specific tolerance through delivery of allergens expressed and secreted by L.lactis bacteria. Stallergenes and ActoGeniX have already carried out a successful proof-of-principle study in preclinical models.
Bernard Coulie, chief executive of ActoGeniX, said: “The PoP study provides the scientific basis for the applicability of our technology platform in allergen immunotherapy. We are extremely pleased to continue our collaboration with Stallergenes while we focus on progressing our existing pipeline and validating our technology platform in new therapeutic areas."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze